RXRX · Recursion Pharmaceuticals, Inc.
$4.79
+0.01 (+0.22%)
At close · Oct 6
Return incl. dividend (before tax)
Market Cap
$2.00B
Shares
535.34M
Volume · Oct 5
67.28M
Avg daily vol (3M)
19.91M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$4.78
Open$4.16
Day$4.06–4.94
52W close$2.84–6.79
Avg vol 30d20.7M
Short int178.7M · 33.4% float · 12.6d
Short vol59%
Last earningsAug 5, 2026
DataApr 2021–Oct 2026
Filing10-Q · Aug 5
Up next
Next earnings call
Nov 5, 2026
Est · unconfirmed
· in 4 wks
filed Aug 5, 2026
call held May 6, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
-25.4%
Trailing year
Short interest
33.4%
Latest settlement · 12.6 days to cover
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.5 · calm
Equity put/call 0.59
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+34%
above
Price vs 50-day avg
+38%
above
RSI (14)
72
overbought
MACD trend
Positive
52-week position
49%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+32%
trailing
6-month return
+35%
trailing
YTD return
+17%
this year
Relative strength
+23%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $4 — 200d above 50d
Institutional flow
Accumulating
2 of 349 funds reported for Sep 30 · net +1.0K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
33.39% of float · ▼ -0.2% MoM · 12.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
349 holders — near 3-yr high, broad support
Squeeze score
100
high risk · 0–100
Fundamentals
Revenue growth
+27%
Y/Y
EPS growth
+15%
Y/Y
Free cash flow
$-378.3M
Balance sheet
$284.4M
net cash
Quant / Vol
risk profile
Volatility
76%
annualized · 1-yr
Max drawdown
−58%
past year
ATR
6.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed May 6, 2026
Cash opex
· 2026
Non-GAAP
up to $390M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+34%
Bullish
Price vs 50-day avg
+38%
Bullish
RSI (14)
72
Bearish
MACD trend
Positive
Bullish
52-week position
49%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $3 › 200d $4 — 200d above 50d
Institutional flow
Accumulating
2 of 349 funds reported for Sep 30 · net +1.0K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
33.39% of float · ▼ -0.2% MoM · 12.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
349 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $3
Now $5 · 49%
Range high $7
vs 200-day avg +34%
vs 50-day avg +38%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cash operating expense (six months ended June 30, 2026) non-GAAP | $191M | six months ended June 30, 2026 | — |
| upfront and milestone payments from the Sanofi collaboration (cumulative) | $134M | Q2 2026 | — |
| upfront and milestones payments from the Roche and Genentech collaboration (cumulative) | $216M | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RXRX
this stock
Recursion Pharmaceuticals, Inc.
|
$2.00B | +16.9% | +26.9% | — | 33.4% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.1% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -5.9% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +589.1% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RXRX | +29.2% | +31.7% | +35.0% | +15.7% | +16.9% |
| SPY | +1.2% | +0.6% | +11.6% | +1.6% | +13.6% |
| vs SPY | +28.0% | +31.1% | +23.5% | +14.1% | +3.3% |